Navigation Links
Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
Date:3/11/2013

SOUTH EASTON, Mass., March 11, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher , President and CEO, will present a corporate overview at SeeThruEquity's Spring Investor Microcap Forum on Tuesday, March 12th at 3:20 pm EDT.  The Investor Forum is being held at the Penn Club, 30 West 44th Street, New York, NY. Registration for the Investor Forum is available at www.seethruequity.com.

Mr. Schumacher's presentation will be webcast and may be viewed on the day of the presentation and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com).

About SeeThruEquity LLC:SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on small- and micro-cap companies with less than $1 billion in market capitalization. These companies are typically underserved by the traditional Wall Street analyst establishment. SeeThruEquity is unfettered by any ties to investment banking or trading, and distributes its high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to its own audience of investors from its corporate website.

SeeThruEquity's philosophy is focused on delivering an unbiased, institutional quality research product for uncovered or under covered companies to all levels of investors in the investment community and at absolutely no charge to the reader of the research or the company being covered. The firm seeks to build relationships between corporate issuers and institutional and sophisticated investors via compelling investor conferences and forums as well as non-deal road shows.

About Pressure BioSciences, Inc.Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.comInvestor Contacts: Richard T. Schumacher, President and CEO, PBI 

(508) 230-1828 (T)Conrad F. Mir, CFO, PBI

(508) 230-1828 (T)Timothy J. Connor, Managing Director, Benchmark Advisory

(858) 568-7059 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
2. India Wound Care Management Market Outlook to 2018 - Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Others
3. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
4. Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
5. North America Wound Care Management Market Outlook to 2018 - Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Other
6. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
7. Global Medical Device Marketing Groups Respond to Internal Cost Pressures
8. Flexpoint Completes Certification for Pressure Relief Device
9. Lower Copayments and Use of Mail-Order Pharmacy may Reduce Disparities in Adherence to Blood-Pressure Medication
10. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
11. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):